EN | RU
EN | RU

Help Support

Back

Is early Tofacitinib administration safe in COVID-19 pneumonitis patients?

Tofacitinib Tofacitinib
Tofacitinib Tofacitinib

What's new?

In patients with COVID-19 pneumonitis, high-dose Tofacitinib therapy is safe and may delay the progression to respiratory failure.

A randomized controlled trial depicted that in people having COVID pneumonitis, 10 mg Tofacitinib twice daily for 2 weeks prevents deterioration to respiratory failure and has a favorable safety profile. Alessia Ferrarini et al. sought to determine the impact of promptly adding Tofacitinib to conventional treatment for hospitalized patients with mild to severe COVID-19 pneumonitis.

The conventional therapy alone or Tofacitinib (10 mg/bid) for 2 weeks, beginning during the first 24 hours of admission, was randomly administered to COVID-19 pneumonitis patients who did not need mechanical ventilation. Overall, 116 volunteers were randomly assigned; 49 in the experimental group finished the 14-day intervention period, 9 stopped taking Tofacitinib as their condition deteriorated and were analyzed, and 1 passed away from respiratory failure. The study was finished by all 58 control participants. The research groups had comparable demographic and clinical characteristics.

By day 14, 15.5% (9/58) of the Tofacitinib group's patients advanced to non-invasive ventilation (continuous positive airway pressure [CPAP]) to maintain SO2 more than 93%, invasive mechanical ventilation, or death, which is significantly less than the volunteers in the control group (20/58, 34.4%, relative risk [RR] 0,45, relative risk reduction [RRR] -55%, number needed to treat [NNT] 5). There were no inter-group variations in the occurrence of serious adverse effects. Therefore, early administration of Tofacitinib is beneficial and safe in COVID-19 pneumonitis patients.

Source:

The European Journal of Clinical Investigation

Article:

Early administration of Tofacitinib in COVID-19 pneumonitis: An open randomised controlled trial

Authors:

Alessia Ferrarini et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: